ThermoGenesis Holdings, Inc. · OTC:THMO
ThermoGenesis — Investor Presentation (June 2010)
24 slides from ThermoGenesis's investor presentation, June 2010
Slide 1: ThermoGenesis Corp. Investor Presentation
ThermoGenesis Corp. Investor Presentation June 2010 1 Revision #1
Slide 2: Safe Harbor
Safe Harbor Certain matters discussed in this presentation are "forward-looking statements." These forward-looking statements can generally be identified as by the context of the statement that includes words such as the Company "expects expects," "anticipates" anticipates or words of similar import
Slide 3: ThermoGenesis: Mission & Business Model
ThermoGenesis: Mission & Business Model • Mission: Design, develop and commercialize cell processing products that enable the practice of regenerative g medicine through g the collection,, separation and storage of adult stem cells • Business B i Model: M d l The Th sale l off medical di l devices d
Slide 4: ThermoGenesis: Momentum Strong
ThermoGenesis: g Momentum Strong • Technology gy leader for collection/processing /p g of stem cells from cord blood/bone marrow • Solid customer base (largest worldwide private, and largest U.S. public cord blood bank under contract) • Recent new product introductions in growing bone marrow segment
Slide 5: New Leadership, New Focus
New Leadership, New Focus Name Position Experience J. Melville Engle CEO, Director Dey L.P. , Anika, Allergan Matthew T. Plavan EVP, COO, CFO McKesson, StrionAir, Reason Inc Hal Baker VP, Commercial Operations Pall, Caridian, BCT Jorge Artiles Chief Quality/Regulatory Officer Medtronic, Baxter, Abbo
Slide 6: Growth Strategy
Growth Strategy • Achieve top line growth, operating efficiencies g • Ride the wave of regenerative market expansion p • Insist on highest product quality to delight our customers gp • Continue existing product g growth • Launch new products and develop new indications with existing products • Partn
Slide 7: Recent Accomplishments
Recent Accomplishments • Signed global Res-Q™ 60 BMC (Res-Q) Distribution Agreement with GE Healthcare • Submitted 510(k) for Res-Q PRP in February • Signed new Distribution Agreement to extend global reach for bone marrow products d t ini Asia A i and d Central/South C t l/S th America A i • Sign N
Slide 8: U.S. Regenerative Medicine Market: Poised for Significant Growth
U.S. Regenerative Medicine Market: Poised for Significant Growth Other 1% Orthopedic Indications Nerve Repair 19% 36% Cardio-vascular 29% Anti- Inflammatory 8% Source: Robyn Young, Stem Cell Summit, 2009, pg. 16: U.S. market: $8.1 billion by 2018 8
Slide 9: Our Key Product Lineup
Our Key Product Lineup Cord Blood • AXP – Cord Blood Stem Cell Banking • Manual Processing – Cord Blood Stem Cell Banking • BioArchive – Stem Cell Cryopreservation and Storage Bone Marrow • MXP™ MarrowXpress™ (MXP) – Laboratory Stem Cell Processing g • Res-Q – Point-of-Care Stem Cell Processing 9
Slide 10: Cord Blood Processing Market ($55M) and Share
Cord Blood Processing Market ($55M) and Share Dual Sites Public Private (Public & Total Private) Total number of CBB 170 215 13 398 Number of CB Processing Banks 132 146 13 291 Annual Collections-Market - Automated 45,000 142,000 13,600 200,600 - Manual 23,000 150,000 88,600 261,600 Total 68,000 292
Slide 11: Cord Blood Storage Market ($37M) and Share
Cord Blood g Market ($ Storage ($37M) ) and Share Public Private Total No. of Cord Banks 177 221 398 No of Storage Banks No. 143 153 296 Storage Market Size $16M $21M $37M ($) BioArchive Customers 76 26 102 BioArchive Customer 53% 17% 52% Share Source: ThermoGenesis estimate for 2010 11
Slide 12: AXP Cord Blood Product Description
AXP Cord Blood Product Description • The most innovative automated cell capture and isolation system on the market (device and disposables) • Avoids contamination risk • cGMP compliant data management Highest Stem Cell Yield* Automated AXP (-HES) ~ 98%* Easil Scalable Easily Manual HES ~ 81.5% • Ind
Slide 13: BioArchive Product Description
BioArchive Product Description • State-of-the-art stem cell storage system • Controlled rate freezing – 1-2C/min • Correct storage temperature - 196C • Minimum transient warming events Preserves Cell Viability CFU-C Recovery 96± 4.8% Source: Dobrila et al. “ThermoGenesis AXP and BioArchive Systems f
Slide 14: GE Healthcare
GE Healthcare • AXP distribution in U.S. and approximately 30 countries throughout the world • Contract extended February 1, 2010, expires July 31, 2012 (renewable) • Significant increase in GEHC sales & marketing funding • Revitalized collaborative sales effort with ThermoGenesis: one face to the c
Slide 15: MXP Bone Marrow Product Description
MXP Bone Marrow Product Description • AXP derivative • Automated laboratory processing of stem cells from bone marrow (device ( and disposables) • High MNC recovery (>85%) • High RBC depletion (>90%) • Fast processing time (40 minutes) • Closed system • 6 units processed during 1 centrifugation 15
Slide 16: Res-Q Product Description
Res-Q Res Q Product Description • Disposable, p , automated point-of-care p solution for preparation of cell concentrate from bone marrow • High MNC recoveries-greater than 80% in 6 cc’s of final product p • Simple procedure. Easy-to-learn and operate • Fast processing time (15 minutes) • Flexible f
Slide 17: Celling Technologies Partnership
Celling Technologies Partnership • Celling Technologies (a subsidiary of Spine Smith, LLC) utilizes MXP and Res-Q technology − Combines stem cell concentrates from bone marrow with proprietary implants to promote bone growth for spinal fusion • Strong in in-the-field the field results results—cell c
Slide 18: Sales/Distribution Strategy
Worldwide Distribution Sales/Distribution Footprint Strategy Product Distributor Region U.S. and Canada, and approximately 30 countries throughout GE Healthcare the world AXP System CEI 9 countries in Latin America Fenwal, Inc. China, India, Japan ThermoGenesis All other countries U.S. orthopedic in
Slide 19: Product Pipeline
Product Pipeline Fiscal Year PRODUCT 2009 2010 2011 2012 2013 MXP Res-Q: Q Bone Marrow Res-Q: PRP R&D/BUSINESS DEVELOPMENT Adipose Stem Cell Biomaterial Composites Concept Development Expected Phase Underway Revenue 19 Generation
Slide 20: First Nine Months of Fiscal Year 2010 Financial Highlights
First Nine Months of Fiscal Year 2010 g g Financial Highlights • First nine months of 2010 Revenues + 1% over prior i year same period i d • Disposable revenues + 14% over prior year same period • Continued vigilance over management of operating expenses • 8% reduction d i in i net loss l • $10 mill
Slide 21: Fiscal Year 2010 Financial Outlook
Fiscal Year 2010 Financial Outlook • 4Q 10 revenues to exceed $7 million, driven by market expansion p for AXP and continued rollouts of MXP and Res-Q Q • Quarterly operating expenses $2.5-$2.8 million • Achieve breakeven in 4Q 10 and profitability in 1Q 11 • Continue prudent management of balance s
Slide 22: Fiscal Year 2010 Milestones
Fiscal Year 2010 Milestones • Expand BioArchive System, AXP customer base • Fully penetrate Celling Technology Technology’s s customer base with MXP and Res-Q • Add new Res-Q distributors; expand applications beyond orthopedics • Product development activities in new markets markets, such as adipose
Slide 23: Investment Considerations - KOOL
Investment Considerations - KOOL • Growing adult stem cell market • Technology leader for collection/processing of stem cells from cord blood/bone marrow • Solid customer base (largest worldwide private, and largest U.S. public cord blood bank under contract) • Recent new product introductions in gr
Slide 24: Thank You
Thank You Thank You 24